Immunodeficient Mouse Models: Oncology & Immunotherapy Research

Introduction – Addressing Core Industry Pain Points
Drug developers and cancer researchers face three persistent challenges with traditional animal models: poor translation to humans (mouse immune responses differ significantly from human), inability to test human-specific immunotherapies (CAR-T, checkpoint inhibitors require human immune cells), and limited recapitulation of human disease pathology (autoimmune disorders, HIV). Humanized Immune System (HIS) Models – animal models, typically immunodeficient mice, engrafted with human immune cells or hematopoietic stem cells to reconstitute a functional human immune system – solve these problems through humanized preclinical platforms. These models allow the study of human-specific immune responses and are widely used in research on infectious diseases, cancer immunology, autoimmune disorders, and immunotherapy development. HIS models provide a crucial platform for preclinical testing and translational medicine. For pharmaceutical companies, CROs, and academic research institutes, the critical decisions now center on model species (Mouse, Rat), application (Research Institutes, Pharmaceutical Companies), and the engraftment efficiency/human immune cell reconstitution level that determines predictive accuracy for clinical trials.

Global Leading Market Research Publisher QYResearch announces the release of its latest report “Humanized Immune System (HIS) Models – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Humanized Immune System (HIS) Models market, including market size, share, demand, industry development status, and forecasts for the next few years.

The global market for Humanized Immune System (HIS) Models was estimated to be worth US$ 268 million in 2025 and is projected to reach US$ 433 million by 2032, growing at a CAGR of 7.2% from 2026 to 2032. Humanized Immune System (HIS) models are animal models, typically immunodeficient mice, engrafted with human immune cells or hematopoietic stem cells to reconstitute a functional human immune system. These models allow the study of human-specific immune responses and are widely used in research on infectious diseases, cancer immunology, autoimmune disorders, and immunotherapy development. HIS models provide a crucial platform for preclinical testing and translational medicine.

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6094157/humanized-immune-system–his–models

Market Segmentation – Key Players, Model Species, and End-Users
The Humanized Immune System (HIS) Models market is segmented as below by key players:

Key Manufacturers (HIS Model Specialists):

• Charles River – Global leader in preclinical models (NSG, NRG mice).
• Taconic Biosciences – Immunodeficient mouse models (NOG, NSG derivatives).
• Jackson Laboratory – NSG mice and immune-humanized models.
• Inotiv – CRO with HIS model services.
• Janvier – European mouse model supplier.
• Crown Bioscience – CRO with HuCD34+ and HuPBMC models.
• GenOway – French transgenic mouse models.
• Oncodesign Services – HIS models for oncology.
• Champions Oncology – Patient-derived xenograft (PDX) + HIS.
• Miltenyi Biotec – HIS model development and cell engineering.
• BioDuro – CRO with HIS pharmacology services.
• GemPharmatech – Chinese HIS mouse models (NCG, NPG).
• Shanghai Model Organisms – Chinese HIS model provider.
• Biocytogen – Chinese gene-edited mouse models.

Segment by Type (Model Species / Genetic Background):

• Mouse – Dominant species (NSG, NRG, NOG, NCG strains). Higher engraftment efficiency, well-characterized immune reconstitution. Largest segment (~95% market share).
• Rat – Emerging model (humanized immune system rats). Larger size allows more blood draws and tissue sampling. Niche segment (~5% market share, growing).

Segment by Application (End-User Sector):

• Pharmaceutical Companies – Largest segment (~65% market share). Drug discovery, lead optimization, preclinical efficacy studies (immuno-oncology, infectious disease).
• Research Institutes – Academic and government labs, translational research (~35% market share).

New Industry Depth (6-Month Data – Late 2025 to Early 2026)

1. CAR-T preclinical surge – In December 2025, the FDA approved two new CAR-T therapies (for multiple myeloma, ALL), driving demand for HIS models (NSG mice with human CD34+ engraftment) for off-target toxicity and efficacy testing.
2. Next-gen HIS model launch – In January 2026, Taconic Biosciences launched the HuNOG-EXL mouse (humanized cytokine knock-in), enabling better myeloid cell (macrophage, neutrophil) reconstitution for solid tumor modeling.
3. Discrete vs. process manufacturing realities – Unlike process manufacturing (e.g., continuous cell line expansion), HIS model production involves discrete engraftment, colony maintenance, and health monitoring – each mouse is individually injected, housed, and genotyped. Key challenges:
   • CD34+ stem cell engraftment – Human hematopoietic stem cells (cord blood or fetal liver) injected into irradiated NSG pups (1-3 days old). Engraftment success rate 60-80%.
   • Human immune cell reconstitution – Flow cytometry (FACS) to verify human CD45+, CD3+, CD19+, CD14+ cells in peripheral blood (8-16 weeks post-engraftment).
   • Colony maintenance – Immunodeficient mice require sterile housing (IVC cages, autoclaved food/water). Strict SOPs to prevent pathogen contamination.
   • Health monitoring – Quarterly sentinel testing for pathogens (MPV, MHV, MNV, Helicobacter). Positive results require colony quarantine or culling.
   • Graft-versus-host disease (GVHD) – HuPBMC models develop GVHD (2-6 weeks), limiting study windows. HuCD34+ models have longer windows (16-24 weeks) but lower engraftment.
   • Customization lead time – Custom HIS models (specific HLA type, gene knockouts) require 6-12 months development time.

Typical User Case – PD-1 Checkpoint Inhibitor Testing (US Pharma, 2026)
A US pharmaceutical company (top 10 global) used HuCD34+ NSG mice (Jackson Laboratory) to test a novel PD-1/PD-L1 bispecific antibody in a humanized tumor model (patient-derived xenograft + human immune cells). Results:

• Tumor growth inhibition: 78% (HIS model) – correlated with subsequent Phase I clinical response (72%)
• GVHD incidence: 12% (HuCD34+, 16-week window) – acceptable for efficacy study
• Cost per mouse: $1,200 (engrafted) vs. $50 (standard NSG) – 24x higher, but predictive value justified

The technical challenge overcome: low natural killer (NK) cell reconstitution in HuCD34+ models (NK cells require human IL-15). The solution involved using NSG-SGM3 mice (IL-3/GM-CSF/SF knock-in) for better innate immune cell engraftment. This case demonstrates that pharmaceutical companies rely on HIS models for predictive immuno-oncology preclinical testing.

Exclusive Insight – “HuPBMC vs. HuCD34+ Model Selection”
Industry analysis often treats all HIS models as similar. However, application benchmarking reveals distinct model characteristics:

The key insight: HuPBMC models are preferred for short-term (2-6 week) efficacy studies (CAR-T, checkpoint inhibitors) due to rapid engraftment and strong T cell reconstitution. HuCD34+ models are preferred for longer-term (16-24 week) studies (vaccine development, chronic infection) with better B cell and myeloid reconstitution. Manufacturers offering both (Charles River, Taconic, Jackson Lab, Crown Bioscience) capture the full market.

Policy and Technology Outlook (2026-2032)

• FDA Modernization Act 2.0 – 2022 law allows alternatives to animal testing, but HIS models remain preferred for immunotherapy testing (animal rule for biologics).
• EU animal testing regulations (2010/63/EU) – 3Rs (Replacement, Reduction, Refinement) apply. HIS models are considered refined (immunodeficient mice have reduced suffering vs. wild-type models).
• China’s NMPA guidelines for cell therapy – HIS models recommended for off-target toxicity testing of CAR-T/TCR-T products (2024 guidance). Domestic providers (GemPharmatech, Shanghai Model Organisms, Biocytogen) gaining share.
• Next frontier: fully humanized mouse (all immune lineages) – Research prototypes (2026) engraft human hematopoietic stem cells plus human thymus (BLT models) and human cytokine knock-ins, achieving near-complete human immune system reconstitution. Commercialization 2028-2030.

Conclusion
The Humanized Immune System (HIS) Models market is growing at 7.2% CAGR, driven by CAR-T/immunotherapy pipeline growth, FDA approvals, and demand for predictive preclinical models. Mouse models dominate (95% share) with NSG/NOG/NRG strains as industry standard. Pharmaceutical companies are the largest end-users (65% share). HuPBMC models are preferred for short-term efficacy studies; HuCD34+ models for long-term chronic studies. The discrete, labor-intensive manufacturing nature of HIS models – stem cell engraftment, flow cytometry reconstitution verification, sterile colony maintenance, GVHD management – favors established preclinical model specialists (Charles River, Taconic, Jackson Laboratory, Inotiv, Crown Bioscience, Janvier) and emerging Chinese providers (GemPharmatech, Shanghai Model Organisms, Biocytogen). For 2026-2032, the winning strategy is offering both HuPBMC and HuCD34+ model options, developing next-generation HIS models (myeloid reconstitution, HLA-typed, human cytokine knock-ins), and expanding into rat HIS models (larger size for serial blood draws).

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp